Liu Y.,Third Security |
Ni L.,Hong Kong University of Science and Technology |
Hu C.,Third Security
IEEE Journal on Selected Areas in Communications | Year: 2012
Topology control is an effective method to improve the energy-efficiency and increase the communication capacity of Wireless Sensor Networks (WSNs). Traditional topology control algorithms are based on deterministic model that fails to consider lossy links which provide only probabilistic connectivity. Noticing this fact, we propose a novel probabilistic network model. We meter the network connectivity using network reachability. It is defined as the minimal of the upper limit of the end-to-end delivery ratio between any pair of nodes in the network. We attempt to find a minimal transmission power for each node while the network reachability is above a given application-specified threshold. The whole procedure is called probabilistic topology control (PTC). We prove that PTC is NP-hard and propose a fully distributed algorithm called BRASP. We prove that BRASP has the guaranteed performance and the communication overhead is O(\vert E \vert + \vert V \vert). The experimental results show that the network energy-efficiency can be improved by up to 250% and the average node degree is reduced by 50%. © 2012 IEEE.
Liu C.-X.,Third Security
Advanced Materials Research | Year: 2014
The public security industry standard “General technical requirements for micro-dose X-ray transmission body scanner” (GA 926-2011) was released in March 25, 2011 and was formally implemented in July 1, 2011.The X-ray radiation performance index of micro-dose X-ray transmission body scanner includes Dose Per Inspection and Leakage Radiation Rate. The standard requires that Dose Per Inspection should be tested by ionization dosimeter. However, it doesn't specify which kind of equipment should be used to test Leakage Radiation Rate, and only requires a high sensitivity dosimeter. Therefore it is necessary to synthetically consider numerical features and test accuracy requirements, select appropriate test methods and test equipments. Radiograph Method, Ionization Detection Method, Scintillation Detection Method and Semiconductor Detection Method are analysed and compared from the detection principle, the advantages and disadvantages, Ionization Chamber Dosimeter was selected to test Dose Per Inspection, Scintillation Detection Method was selected to test Leakage Radiation Rate. © (2014) Trans Tech Publications, Switzerland.
Hu C.-L.,Third Security
Proceedings of 2012 International Conference on Image Analysis and Signal Processing, IASP 2012 | Year: 2012
The FIR filter is widely used in digital communication and control systems. This paper presents an analysis in detail of the principle of the FIR filter, and selects the proper window function to cut off impulse response, then presents the designing process with the aided tool in fdatool for obtaining the unit impulse response sequence. It also analyzes the FIR realization on DSP and gives the key program. The FIR filter conducts in AD interrupt service program after the converting of AD sample. Finally, it proposes a simple and rigorous validation scheme for this design with Fourier decomposition. The result shows that the FIR filter is accurate, stable, and enjoys a strong practicability and reliability. © 2012 IEEE.
Yang Y.,Third Security
Applied Mechanics and Materials | Year: 2014
In this project, Labview programming language is used to design the control system of an elevator for multiple users. Based on the use of visual programming by Labview, the project establishes a graphical soft panel, instead of traditional instrument control panel and programming interface, to run logical updates and operation maintenance easily. Labview is corresponding to the ports of many companies' instruments, which makes easy to regulate and control relevant operations. The use of modular design in the project increases system's stability and avoids errors caused by using of mixed data types. © (2014) Trans Tech Publications, Switzerland.
Third Security | Date: 2012-09-28
The present invention relates to a method for generating and check-controlling a network identity identification code in a network electronic identity. The method comprises: a server performing initialization and performing generation and distribution of random numbers; receiving and auditing a request to generate the network identity identification code from a client; if the auditing is passed, performing encryption coding and generating a network identity identification code, and then sending the network identity identification code to a network electronic identification card through the client; the network electronic identification card performing the check processing of a network identity identification code, and feeding back a result to the server; the server storing the network identity identification code into a database, and informing the user. By means of the method for generating and check-controlling a network identity identification code in a network electronic identification card, the purposes of network identity management and privacy protection are both achieved, thereby effectively protecting the network application security and identity information privacy of citizens. The method is convenient and quick in use, has stable and reliable working performance, and has a wide application range, thereby laying a strong foundation for establishment of unified network identity management and service ecosystem.
Third Security | Date: 2016-08-17
The present application relates to a detection method and a detection system for an audio transmission characteristic of a building intercom system. The method comprises: a sound source portion generating a specific voice signal, and inputting the specific voice signal to a detected channel as an input voice signal, transmitting the specific voice signal in the detected channel and outputting the specific voice signal as a detected output voice signal, wherein the specific voice signal comprises an ITU Telecommunication Standardization Sector (ITU-T) P.50 simulated voice signal or P.501 human voice signal; and based on the detected output voice signal, measuring a sound pressure relevant to the detected output voice signal, and according to the sound pressure which is obtained by measurement and is relevant to the detected output voice signal, calculating an audio characteristic parameter value, so as to determine an audio transmission characteristic of the detected channel. By improving a sound source, a backplane and audio distortion measurement, the solution of the present application improves the detection accuracy of an audio transmission characteristic of a simulated (bus-mode) building intercom system and the accuracy of a detection result, so that the detection is closer to an actual use effect.
News Article | March 25, 2010
Cyntellect, a San Diego-based company working on technologies to analyze, purify and process cells, raised $3 million from the sale of debt, equity and options or warrants, according to an SEC filing. The company announced last November it had raised $15.5 million. Early investors in the 13-year-old company include Bru II Venture Capital Fund, Iceland Genomics Ventures, Sigma-Aldrich, Sumitomo, and Third Security. By posting a comment, you agree to our terms and conditions.
News Article | September 3, 2013
Former Dendreon CEO and Dendreon Bull Start New Biotech Hedge Fund Mitch Gold made a lot of money as the CEO of Dendreon (NASDAQ: DNDN), the Seattle-based cancer drug developer. David Miller made his reputation as an investment analyst with in-depth, bullish reports on the company. Now these two are going to work together on a new Seattle-based biotech hedge fund called Alpine BioVentures. Gold isn’t saying how much of his money he’s putting into Alpine, but it will be “a modestly sized fund” in the “multiple millions” at the start. Gold says he plans to spend about half his time on the fund, with the other half going toward his cancer immunotherapy startup, Alpine Biosciences. Miller, the president of Biotech Stock Research, is stepping back from the company he co-founded in 1999 and will no longer write his independent research reports now that he’s managing money. Alpine’s plan is to do fundamental research, and invest in companies with strong technology and potential to improve patients’ lives, Gold says. The fund is starting out by “primarily” managing Gold’s money, but it intends to add additional outside investors over time once it has a track record, Gold says. Alpine also intends to make occasional investments in private companies that have a chance of making a big impact on patients, and generating near-term liquidity, he says. R.J. Kirk’s Third Security, Arie Belldegrun’s Two River, and Baker Brothers Advisors all offer good models for public/private biotech investment, Gold said. Gold and Miller’s new venture is getting started during a clear upswing for the highly volatile biotech industry. There have been 31 initial public offerings of biotech companies this year, about triple the usual volume seen in the years following the financial crisis of 2008. The NASDAQ Biotech Index has surged 41 percent this year, compared with about a 19 percent gain year-to-date in the broader NASDAQ Composite Index. Some of that surge can be explained by investors becoming increasingly aware of a number of good drugs in development, Gold says. “You’re seeing a lot of interesting developments in cancer and rare diseases, and I want to be a part of it,” Gold said. Miller said he sees a lot of opportunities, but he also has a personal motivation to try something new. “After 14 years of writing about [biotech investing], for me, it’s time to do it,” Miller said. He adds: “I have a great deal of respect for Mitch and what he was able to build at Dendreon and before that. He’s got a track record of success. I’m really excited about taking our combined 30-plus years of experience in biotech and applying it in a new way.” Gold and Miller crossed paths over the past 10 years when Gold was running Dendreon and Miller was an analyst covering the company. Gold raised about $2 billion in capital for the company and became known for making bold statements about how Dendreon was bound to transform the lives of prostate cancer patients. Miller became known in those years for his unwavering belief in Dendreon’s technology, and his criticism of the company’s marketing strategy and execution. Gold was replaced by John H. Johnson as CEO of Dendreon in February 2012, after the company stumbled in the early days of marketing its drug, sipuleucel-T (Provenge). He stepped down from the Dendreon board a year later. While many shareholders lost their shirts, Gold did well personally. In one two-day period just after FDA approval in April 2010, Gold pocked about $26.7 million through sales of Dendreon stock at prices of more than $50 a share. Dendreon closed last Friday at $2.84. Biotech Stock Research (BSR) will continue to publish research reports by co-founder Alan Leong, Miller said, although the company’s coverage universe will be scaled back. As a portfolio manager making day-to-day investment decisions, Miller will no longer author the independent research reports that BSR is known for. He said he wants to avoid conflicts of interest that he says plague so many research reports on public companies. Although Miller won’t be writing detailed independent research reports any more, he does plan to stay engaged in the public conversation about biotech stocks that occurs daily on Twitter. His new Twitter account is @AlpineBV_miller. “I don’t think there’s any way to do this job without Twitter,” Miller said. “And the only way to get the best out of Twitter is to participate and not be a lurker.” Gold said he wanted Miller as a portfolio manager for a number of reasons. “What I liked about David is he comes to his research with a real independent mind, and can look at companies from a scientific perspective. I like that. We didn’t always agree on things, which is good. I wanted an original thinker. He’s also got an incredible work ethic, and he’s hungry to be successful.” Both Miller and Gold emphasized their desire to build the Alpine fund in Seattle. “Both Mitch and I are big believers in Seattle as a biotech space,” Miller said. “We see there are great funds here, but not a lot of them. The opportunity when we’re successful to grow the fund here, and operate in Seattle, is icing on the cake for us. We’re both pretty passionate about it.”
News Article | April 15, 2015
OMAHA, Neb.--(BUSINESS WIRE)--Transgenomic, Inc. (NASDAQ: TBIO) today provided a business update and financial review for the year ended December 31, 2014. “In 2014, we made good progress in building a foundation for renewed growth at Transgenomic,” said Paul Kinnon, Transgenomic’s President and Chief Executive Officer. “We executed on the development of Multiplexed ICE COLD-PCR (MX-ICP) in 2014, setting the stage for validation of the product in 2015 and its launch in the second quarter. A key recent development is that we have added the capability to use MX ICP quantitatively on sequencing platforms. This further expands the commercial potential of MX-ICP and its potential to enable the adoption of truly personalized, or precision medicine. We also continued to make progress strengthening our designated core businesses and resolving several infrastructure issues that have been obstacles to greater success over the past year.” Mr. Kinnon continued, “MX-ICP has the advantage that it works with all current sequencing platforms to make possible the minimally-invasive detection and monitoring of genetic alterations that we believe are essential to the wide adoption of personalized medicine and treatment. The ability of MX-ICP to reduce or eliminate the need for costly and painful tissue biopsies, its ultra-high sensitivity and simplicity, and its unparalleled flexibility to work with all types of patient samples and with all genetic analysis platforms make it the ideal enabling technology for the nascent revolution in cancer treatment. MX-ICP will, we believe, accelerate the growth of the cancer diagnostics market, which we estimate is currently in excess of $2.5 billion annually. The fact that MX-ICP is valuable across industry segments, including laboratory equipment manufacturers, major biopharmaceutical firms and clinical laboratory companies, further strengthens our confidence in our strategy of focusing on licensing and partnerships to achieve broad and rapid adoption of MX-ICP in the research and clinical markets. Another validation of our approach was our success in recently recruiting a senior industry executive with a stellar business development background to oversee the business development campaign for MX-ICP.” “Along with our progress in laying the groundwork for ramping up the commercial launch of MX-ICP over the rest of the year, we also have worked to solidify the current businesses we view as core, such as our Patient Testing business, which recorded good growth in the fourth quarter of 2014 and year-over-year. In addition, we expect the ability to perform MX-ICP for clinical studies for our Pharma and Biotech clients is a major opportunity for revenue generation in our Biomarker Identification business, with the aim of bringing on new clients and new projects in 2015,” said Mr. Kinnon. Mr. Kinnon added, “We are optimistic that the issues with receivables we saw during the implementation of our new billing and LMS system are behind us, as our new systems are coming fully on board. We also believe that redeploying selected non-core assets as we did with our SURVEYOR business last year makes good sense, and we may execute additional transactions of this type going forward. We are optimistic that as we head further into 2015 we are well positioned to capitalize on the value of the MX-ICP technology.” Review of Fourth Quarter Financial Results Net sales for the fourth quarter of 2014 were $7.7 million compared with $6.2 million for the same period in 2013, an increase of 24%. Sales in the Laboratory Services segment increased 73% from the comparable period last year, primarily reflecting higher sales in our Patient Testing business, which were spurred by a number of new products launched in late 2013. These gains were partially offset by lower sales in our Contract Laboratory services business. In the Genetic Assays and Platforms segment, net sales in the fourth quarter of 2014 declined $0.6 million as compared to the same period in 2013, primarily due to the sale of Transgenomic’s Surveyor Kits product line during the third quarter of 2014, which resulted in lower sales of bioconsumables. Operating expenses were $8.4 million during the fourth quarter of 2014, compared with $5.7 million in the prior year period. The $2.7 million increase in operating expenses was primarily due to a higher bad debt provision in the fourth quarter of 2014 as compared to the fourth quarter of 2013, partially offset by lower stock compensation costs. The net loss for the fourth quarter of 2014 was $5.8 million, or $0.77 per share, compared with a net loss of $4.0 million or $0.57 per share for the fourth quarter of 2013. Cash and cash equivalents were approximately $1.6 million at both December 31, 2014 and December 31, 2013. Modified EBITDA, which is a non-GAAP measure that Transgenomic views as an appropriate and sound measure of the company's results, showed a loss of $5.2 million for the fourth quarter of 2014, compared to a loss of $2.7 million for the same period in 2013. A reconciliation of Net Loss to Modified EBITDA is presented below. Review of 2014 Full Year Financial Results Net sales for the twelve months ended December 31, 2014 were $27.0 million, compared with $27.5 million for the same period in 2013. The $0.5 million decline includes a 13% decrease in the Genetic Assays and Platforms segment as a result of lower instrument sales and lower bioconsumables sales resulting from the sale of our Surveyor Kits product line during 2014. The Company also recorded lower sales in the Laboratory Services segment of its Contract Laboratory services business. These decreases were partially offset by a 23% increase in Patient Testing sales in 2014, reflecting the impact of new products launched in late 2013, as well as sales increases in the core Laboratory Services business itself. Gross profit was $9.7 million, or 36% of net sales in 2014, compared with gross profit of $10.8 million, or 39% of net sales for the same period in 2013. The decrease was largely attributable to lower sales in the Contract Laboratory services business and lower revenues from instrument and bioconsumables sales in the Genetic Assays and Platforms segment. These decreases were partially offset by increased gross profit from Patient Testing sales. Operating expenses were $27.0 million in 2014, compared with $26.5 million in 2013. The increase is primarily due to higher provisions for bad debt in 2014 as compared to 2013, partially offset by decreased stock compensation and amortization costs. For the twelve months ended December 31, 2014 and 2013, non-cash income related to warrant revaluation was $0.5 million and $0.3 million, respectively. As previously disclosed, in July 2014, Transgenomic sold the rights to its SURVEYOR Nuclease technology and assets for a minimum of $4.25 million in cash. During the third quarter of 2014, the Company recorded a net gain of $4.1 million as a result of this sale. The net loss for the twelve months ended December 31, 2014 was $13.9 million or $2.01 per share, compared with a net loss of $16.0 million, or $2.30 per share, for the comparable period of 2013. As previously announced, during the first quarter of 2014, the Company completed a financing that raised $7 million from affiliates of Third Security, LLC, a leading life sciences investment firm. The net proceeds from this financing were used to pay down a revolving credit line and for working capital and other general corporate purposes. During the fourth quarter of 2014, Transgenomic completed financings that raised approximately $3.1 million in net proceeds. These proceeds were used for working capital and other general corporate purposes. Conference Call Transgenomic management will host a conference call to discuss the business and financial update at 5:00 p.m. Eastern Time today. To access the call via telephone, please dial 866-952-1907 from the U.S. or Canada or 785-424-1826 for international participants and enter conference ID TRANS. The call also will be broadcast live over the Internet. To listen to the webcast, please log onto the Company’s Investor Relations web page at http://www.transgenomic.com/investor-relations/quarterly-conference-calls and follow the instructions. An archived webcast of the call will be available for 30 days. A telephone replay will be available from 8:00 p.m. Eastern Time April 15, 2015 through 11:59 p.m. Eastern Time on April 29, 2015 by dialing 800-839-1232 (domestic) or 402-220-0460 (international). About Transgenomic Transgenomic, Inc. is a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through advanced diagnostic technologies, such as its revolutionary ICE COLD-PCRTM and its unique genetic tests provided through its Patient Testing business. The company also provides specialized clinical and research services to biopharmaceutical companies developing targeted therapies and sells equipment, reagents and other consumables for applications in molecular testing and cytogenetics. Transgenomic’s diagnostic technologies are designed to improve medical diagnoses and patient outcomes. Forward-Looking Statements Certain statements in this press release constitute “forward-looking statements” of Transgenomic within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements include, but are not limited to, those with respect to management's current views and estimates of future economic circumstances, industry conditions, company performance and financial results, including the ability of the Company to grow its involvement in the diagnostic products and services markets, expectations regarding new clients, projects and prospects, MX-ICP’s ability to accelerate the Company’s growth and generate revenue, and the operation of our billing systems. The known risks, uncertainties and other factors affecting these forward-looking statements are described from time to time in Transgenomic's filings with the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. Accordingly, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 with respect to all statements contained in this press release. All information in this press release is as of the date of the release and Transgenomic does not undertake any duty to update this information, including any forward-looking statements, unless required by law.